At a Glance
- Companies: Foresee Pharmaceuticals; Primevera Therapeutics
- Location: Taipei, Taiwan (Foresee)
- Deal value: $10m upfront; up to $584.5m milestones; single‑digit royalties; Primevera receives 19% equity stake in Foresee
- Focus area: MMP‑12 inhibitors (FP‑025, FP‑020 and discovery assets) for fibrotic and inflammatory diseases
- Next steps: Primevera to advance preclinical and clinical development globally
What happened?
Foresee Pharmaceuticals has licensed exclusive global rights to its portfolio of MMP‑12 inhibitors—including clinical candidate FP‑025, preclinical FP‑020 and early discovery assets—to Primevera Therapeutics. The transaction includes $10 million upfront, up to $584.5 million in development, regulatory and commercial milestones, single‑digit royalties on net sales, and a 19% equity stake for Primevera in Foresee.
Why does it matter?
Matrix metalloproteinase‑12 (MMP‑12) is a key driver of macrophage‑mediated inflammation and fibrosis in diseases like idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and atherosclerosis, where current therapies fail to address underlying pathology. Foresee’s inhibitors have shown preclinical efficacy in halting disease progression, and licensing them to a focused player like Primevera allows accelerated global development while providing Foresee non‑dilutive capital and retained upside.
Who’s behind it?
Foresee Pharmaceuticals is a Taiwan‑based clinical‑stage biotech specialising in MMP inhibitors, with FP‑025 having completed phase 1 and showing promise in fibrotic indications. Primevera Therapeutics is an emerging player leveraging the assets to build a fibrosis/inflammation franchise, gaining a significant minority stake to align incentives.
How was it achieved?
The licence covers all three MMP‑12 programmes, with Primevera assuming full responsibility for manufacturing, preclinical/clinical studies, regulatory filings and commercialisation worldwide. Financial terms reflect a balanced risk/reward structure, with Foresee receiving immediate cash, long‑term biobucks and royalties, plus Primevera’s equity stake ensuring shared commitment to value creation.
What’s next?
Primevera is expected to prioritise FP‑025 into phase 2 trials in fibrotic lung disease or similar indications, leveraging preclinical data on lung protection and anti‑inflammatory effects. Foresee will redirect resources to other pipeline assets, while the equity stake provides Primevera skin‑in‑the‑game governance influence.
What are people saying?
Foresee’s leadership framed the deal as a “strategic monetisation” that funds core operations while retaining economic participation in MMP‑12’s success through milestones and royalties. Primevera highlighted the programmes’ “compelling preclinical profile” and potential to address unmet needs in fibrosis, where selective MMP‑12 inhibition could offer disease modification.